London-based biotech Purespring Therapeutics plans to bring their kidney-tweaking gene therapy to the clinic with the help of a new £80 million (about $105 million) pool of series B cash.

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Biotechnology company Purespring Therapeutics has ...

Cross-sectional images of IgA nephropathy murine kidneys. Purespring gene therapy significantly improves kidney morphology and reduces the areas of scarring and fibrosis stained in blue. Results ...

The trial is scheduled to commence in the fourth quarter of this year, with subject recruitment in both Europe and the US.

Purespring Therapeutics Ltd. has raised £80 million (US$104.6 million) in a series B, putting it on course to be the first to take a gene therapy for a kidney disease into the clinic. The money ...

Purespring’s platform approach enables streamlined gene therapy development for both acquired and genetic renal diseases, offering the potential to halt, reverse and even cure both rare and ...

News broke yesterday that researchers in Philadelphia appear to have successfully treated a 6-month-old baby boy, called KJ, with a personalized CRISPR gene-editing therapy.The treatment corrects ...